Technology | October 08, 2009

New MRA Agent Challenges X-Ray Angiography in AIOD

October 8, 2009 – Lantheus Medical Imaging Inc. said two oral presentations featuring gadofosveset trisodium, the first and only FDA cleared blood pool contrast agent for magnetic resonance angiography (MRA), were presented at MRA-Club 09: The 21st Annual International Conference on Magnetic Resonance Angiography. 

The company also announced today that ABLAVAR has been chosen as the brand name for gadofosveset trisodium. ABLAVAR (gadofosveset trisodium) is a blood pool contrast agent approved for magnetic resonance angiography to evaluate aortoiliac occlusive disease (AIOD) in patients with known or suspected peripheral vascular disease. The unique albumin-binding properties of ABLAVAR make it ideal for vascular imaging allowing multiple images to be obtained using a single, low dose injection. ABLAVAR enables the visualization of both arterial and venous blood vessels. ABLAVAR is clinically proven to produce high resolution MRA images, combining both dynamic (first pass) and steady state imaging, resulting in diagnostic accuracy comparable to X-ray angiography, the current standard of care for diagnosing vascular disease such as AIOD.

ABLAVAR is indicated for use as a contrast agent in magnetic resonance angiography (MRA) to evaluate aortoiliac occlusive disease (AIOD) in adults with known or suspected peripheral vascular disease.
 
The first presentation entitled, “An Update on the Clinical Experience with Gadofosveset,” was presented by Mark G. Hibberd, M.D., Ph.D., senior medical director, global medical affairs, Lantheus Medical Imaging Inc. This presentation included the review of safety and efficacy data from the clinical use of ABLAVAR in Europe and Canada (over three years of marketing data) and from the FDA approval of MS-325 in December 2008. The establishment of a new clinical registry in the United States was also announced. The presentation confirmed that ABLAVAR has not been associated with nephrogenic systemic fibrosis (NSF) to date.
 
The second oral presentation, “A Re-analysis of MS-325 (Gadofosveset Trisodium) Clinical Trial Data in Support of U.S. FDA Approval,” was given by Edward Parsons, Ph.D., formerly of EPIX Pharmaceuticals Inc. and currently a consultant to Lantheus Medical Imaging Inc. This presentation, which reported a blinded, independent re-read of images from previous phase 3 studies, found that ABLAVAR demonstrated statistically greater sensitivity (detecting disease when present) compared with noncontrast MRA.  The study also showed that ABLAVAR had noninferior specificity (excluding disease when not present) with noncontrast MRA1.  Thus ABLAVAR MRA images provided diagnostic accuracy superior to non-contrast MRA and comparable to traditional X-ray angiography."  
 
“The data presented at the recent MRA Club meeting supports the safety and efficacy of ABLAVAR, a first-in-class imaging agent we are planning to introduce to the U.S. market in the coming months,” said Dr. Hibberd.  “We are confident that ABLAVAR will make it possible for physicians to detect aortoiliac occlusive disease less invasively than with the current gold standard – X-ray angiography – and, importantly, without exposing the patient to ionizing radiation.  Furthermore, ABLAVAR is used in a single low dose which allows both first pass and high resolution blood pool imaging.”
 
In April 2009, Lantheus Medical Imaging acquired the U.S., Canadian, and Australian rights to gadofosveset trisodium (formerly known as MS-325) from EPIX Pharmaceuticals Inc. The product is approved in 38 countries worldwide and has been used in more than 60,000 patients in Europe.
 
For more information: www.radiopharm.com 

Related Content

Imaging agent helps predict success of lung cancer therapy
News | Oncology Diagnostics | March 08, 2018
March 8, 2018 – Doctors contemplating the best therapy for...
OptiStar Elite injector
Feature | Contrast Media Injectors | March 07, 2018 | Grand View Research Inc.
The global contrast media injectors market is expected to reach $1.4 billion by 2025, growing at a compound annual...
TriHealth in Cincinnati

TriHealth in Cincinnati.

Sponsored Content | Case Study | Contrast Media Injectors | March 06, 2018
The continuing search for advantages to improve workflow has radiology departments constantly searching for new...
Guerbet Presents Contrast&Care Injection Management Solution at ECR 2018
News | Contrast Media | February 28, 2018
February 28, 2018 — Guerbet will present its new Contrast&Care application, as well as other...
A brain MRI. Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns. Gadolinium deposition in the brain has raised concerns about Gadolinium toxicity.

Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

Feature | Magnetic Resonance Imaging (MRI) | February 16, 2018 | Dave Fornell
One of the biggest concerns in radiology in recent years is the safety of gadolinium-based contrast agents (GBCAs) us
ACR Introduces New Contrast Reaction Card
News | Contrast Media | February 07, 2018
The American College of Radiology (ACR) introduced a new contrast reaction card that summarizes important steps to be...
Bracco Diagnostics' MultiHance Contrast Agent Earns Expanded Approval for Pediatric MRI
News | Contrast Media | January 30, 2018
Bracco Diagnostics Inc. announced the labeling of its contrast agent MultiHance has obtained U.S. Food and Drug...
Study Finds No Evidence that Gadolinium Causes Neurologic Harm

MR images through, A, C, E, basal ganglia and, B, D, F, posterior fossa at level of dentate nucleus. Images are shown for, A, B, control group patient 4, and the, C, D, first and, E, F, last examinations performed in contrast group patient 13. Regions of interest used in quantification of signal intensity are shown as dashed lines for globus pallidus (green), thalamus (blue), dentate nucleus (yellow), and pons (red).

News | Contrast Media | January 11, 2018
January 11, 2018 — There is no evidence that accumulation in the brain of the element gadolinium speeds cognitive dec
Male Triathletes May Be Putting Their Heart Health at Risk
News | Cardiac Imaging | January 09, 2018
Competitive male triathletes face a higher risk of a potentially harmful heart condition called myocardial fibrosis,...
Overlay Init